Literature DB >> 16622303

Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.

Yutaka Mori1, Yohta Itoh, Tohru Obata, Naoko Tajima.   

Abstract

To investigate the relationship between insulin resistance, postprandial hyperglycemia, postprandial hyperlipidemia, and oxidative stress in type 2 diabetes, changes in postprandial glucose, triglyceride, and nitrotyrosine levels vs baseline after diet loading were examined in type 2 diabetic patients given pioglitazone (PG) or glibenclamide (GB). Twenty-four outpatients with type 2 diabetes treated with oral PG for 6 mo (BMI, 26.3 +/- 0.9; HbA1c, 8.2 +/- 0.2%) and 10 type 2 diabetic patients treated with GB (BMI, 27.4 +/- 1.6; HbA1c, 8.1 +/- 0.2%) at our institutions were compared. These patients were given meal tolerance tests (MTT; each consisting of energy 400 kcal, protein 8.7 g, fat 22.4 g, carbohydrate 41 g) before and 6 mo after administration of either agent. PG produced a significant decrease in FPG, HbA1c, HOMA-R, and TG levels in the subjects compared to baseline. In contrast, GB significantly decreased FPG and HbA1c levels, while not affecting HOMA-R and TG values. While PG produced a significant increase in LPL, HDL-cholesterol, and adiponectin levels, GB did not affect these values. At MTT 6 mo after PG administration, insulin levels before and 4 h after MTT, free fatty acid (FFA) levels 1, 2, and 4 h after MTT, glucose, TG, and RLP-TG levels before and 1, 2, 4, and 6 h after MTT were significantly decreased compared to baseline. At MTT 6 mo after GB administration, while a significant decrease in fasting and 2 h, postprandial glucose values compared to baseline MTT levels was observed, fasting and postprandial TG and RLP-TG levels remained unchanged compared to baseline. After 6 mo of PG and GB administration, serum nitrotyrosine levels before and after MTT were significantly decreased compared to baseline in both groups, while the decrease in nitrotyrosine levels before and after MTT was more marked in the subjects given PG. Our study results suggest that PG suppresses increases in postprandial glucose and TG levels, and improves insulin resistance; and, in addition, that PG may have a favorable impact on oxidative stress in type 2 diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622303     DOI: 10.1385/ENDO:29:1:143

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  17 in total

1.  Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia.

Authors:  A Ceriello; N Bortolotti; E Motz; C Pieri; M Marra; L Tonutti; S Lizzio; F Feletto; B Catone; C Taboga
Journal:  Metabolism       Date:  1999-12       Impact factor: 8.694

Review 2.  The role of nitric oxide in multiple sclerosis.

Authors:  J F Parkinson; B Mitrovic; J E Merrill
Journal:  J Mol Med (Berl)       Date:  1997-03       Impact factor: 4.599

Review 3.  Inducible nitric oxide synthase: what difference does it make?

Authors:  C Nathan
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

4.  Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery.

Authors:  H Kawano; T Motoyama; O Hirashima; N Hirai; Y Miyao; T Sakamoto; K Kugiyama; H Ogawa; H Yasue
Journal:  J Am Coll Cardiol       Date:  1999-07       Impact factor: 24.094

5.  Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice.

Authors:  Ilana Talior; Merav Yarkoni; Nava Bashan; Hagit Eldar-Finkelman
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-08       Impact factor: 4.310

6.  Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation.

Authors:  Lisa Quagliaro; Ludovica Piconi; Roberta Assaloni; Lucia Martinelli; Enrico Motz; Antonio Ceriello
Journal:  Diabetes       Date:  2003-11       Impact factor: 9.461

7.  Expression of inducible nitric-oxide synthase and intracellular protein tyrosine nitration in vascular smooth muscle cells: role of reactive oxygen species.

Authors:  Diana M Fries; Evgenia Paxinou; Marios Themistocleous; Eric Swanberg; Kathy K Griendling; Daniela Salvemini; Jan W Slot; Harry F G Heijnen; Stanley L Hazen; Harry Ischiropoulos
Journal:  J Biol Chem       Date:  2003-04-10       Impact factor: 5.157

8.  Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.

Authors:  Kaoruko Tada Iida; Yasushi Kawakami; Masatsune Suzuki; Hitoshi Shimano; Hideo Toyoshima; Hirohito Sone; Kazunori Shimada; Yoshitaka Iwama; Yoshiro Watanabe; Hiroshi Mokuno; Katsuo Kamata; Nobuhiro Yamada
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-02-04       Impact factor: 4.310

9.  Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia.

Authors:  Ling Tao; Hui-Rong Liu; Erhe Gao; Zhi-Ping Teng; Bernard L Lopez; Theodore A Christopher; Xin-Liang Ma; Ines Batinic-Haberle; Robert N Willette; Eliot H Ohlstein; Tian-Li Yue
Journal:  Circulation       Date:  2003-11-10       Impact factor: 29.690

10.  Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress.

Authors:  Hitoshi Ishida; Makoto Takizawa; Sachihiko Ozawa; Yoko Nakamichi; Shinya Yamaguchi; Hidenori Katsuta; Toshiaki Tanaka; Masahiro Maruyama; Hiroshi Katahira; Katsuhiko Yoshimoto; Eiji Itagaki; Shinya Nagamatsu
Journal:  Metabolism       Date:  2004-04       Impact factor: 8.694

View more
  3 in total

1.  Secondary prevention of stroke: Pleiotropic effects of optimal oral pharmacotherapy.

Authors:  Kiyoshi Kikuchi; Ko-Ichi Kawahara; Naoki Miura; Takashi Ito; Yoko Morimoto; Salunya Tancharoen; Nobuyuki Takeshige; Hisaaki Uchikado; Rokudai Sakamoto; Naohisa Miyagi; Chiemi Kikuchi; Narumi Iida; Naoto Shiomi; Terukazu Kuramoto; Masaru Hirohata; Ikuro Maruyama; Motohiro Morioka; Eiichiro Tanaka
Journal:  Exp Ther Med       Date:  2012-04-24       Impact factor: 2.447

2.  Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study.

Authors:  Nam Hoon Kim; Dong Lim Kim; Kyeong Jin Kim; Nan Hee Kim; Kyung Mook Choi; Sei Hyun Baik; Sin Gon Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2017-06

Review 3.  Clinical neuroprotective drugs for treatment and prevention of stroke.

Authors:  Kiyoshi Kikuchi; Hisaaki Uchikado; Motohiro Morioka; Yoshinaka Murai; Eiichiro Tanaka
Journal:  Int J Mol Sci       Date:  2012-06-21       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.